ProTrans stem cells approved for clinical trials in COVID-19 patients
NextCell Pharma AB ("NextCell") today announces that the application for clinical trial of COVID-19 patients with the drug candidate ProTrans has been approved by both the Ethics Committy and the...
Presentation of the positive results from ProTrans-2
NextCell Pharma AB (“NextCell”) announced earlier this week that the clinical diabetes trial ProTrans-2 had met the primary endpoints. On the occation of that, the principal investigator Professor Per-Ola Carlsson…
ProTrans shows significant effect in Diabetes
Cellaviva's parent company NextCell Pharma AB ("NextCell") today announces that the ProTrans-2 clinical trial met the primary endpoint. Patients treated with a single dose ProTrans show a statistically significant improved...
NextCell approved for trading on Nasdaq First North
NextCell Pharma AB (publ) (“NextCell” or “the Company”) announces that Nasdaq Stockholm AB today has approved their application for trading on Nasdaq Stockholm First North. The last day for trading…
NextCell Pharma AB’s rights issue heavily oversubscribed
The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) announces today the outcome in the Company’s new issue of shares with preferential rights for existing shareholders (the…
NextCell's phase II study is completed – a phase III is being prepared
NextCell Pharma AB (“NextCell”) announces that the last patient now has left ProTrans-2, meaning the phase II trial with the drug candidate ProTrans for treatment of type 1 diabetes, is…
NextCell Pharma AB publishes prospectus relating to the rights issue and announces the intention of change of listing to Nasdaq First North in July
The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) has prepared a prospectus (the “Prospectus”) relating to the new issue of shares with preferential rights for existing…
Invited to panel discussion; Post-Covid-19 world
NextCell Pharma AB (“NextCell”) has been invited to participate in the panel discussion entitled “The impact of corona virus on the global healthcare – new challenges and main problems”. Doctor…
The Board of Directors of NextCell Pharma AB resolves on a fully guaranteed SEK 25.1 million rights issue
NextCell Pharma AB (“NextCell” or the “Company”) announces that the Board of NextCell Pharma AB has resolved to conduct a fully guaranteed new issue of shares of approximately SEK 25.1…
NextCell Pharma AB publishes its interim report for September 2019 - February 2020
NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 – February 29, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reports Second quarter…
NextCell in discussions about patients with covid-19
NextCell Pharma AB (“NextCell”) announces that parallel discussions with several hospitals have been initiated to treat patients with covid-19, the severe respiratory tract infection caused by the new coronavirus, with…
The stem cell company NextCell Pharma is preparing for a pivotal phase III trial
NextCell Pharma AB (“NextCell”) announces that CEO Mathias Svahn will present a status update of the ongoing clinical trials at the Stockholm Corporate Finance Life Science Seminar held at Berns…